Does doxy-PEP work for women?

Not proven yet. Doxy-PEP means taking the antibiotic doxycycline within 72 hours after sex to lower the chance of some bacterial STIs. CDC says it can help some people reduce the chances of getting syphilis, chlamydia and, in some studies, gonorrhoea, and that it does not prevent other common STIs such as HIV or herpes (CDC, Preventing STIs with Doxy PEP, 2026). It is a prescription medicine used under a clinician's care, and this answer does not cover how to take it.

The trial that established it enrolled 501 gay, bisexual and other men who have sex with men and transgender women who were taking HIV PrEP or living with HIV and had had gonorrhoea, chlamydia or syphilis in the previous year (Luetkemeyer and colleagues, New England Journal of Medicine, 2023). With doxycycline, the combined rate of those three infections was about two thirds lower than with standard care. That is strong evidence, but only for the group that was studied.

The first trial in cisgender women randomised 449 Kenyan women aged 18 to 30 who were taking HIV PrEP (Stewart and colleagues, New England Journal of Medicine, 2023). Over 12 months there were 50 new STIs in the doxy-PEP group and 59 in the standard-care group, a difference that was not statistically significant. Hair samples from 50 randomly chosen women in the doxy-PEP group found the drug in only 29% of samples, so use was low, and every gonorrhoea sample was resistant to doxycycline. Interviews with participants later pointed to side effects, pill burden and worries about stigma and partners' reactions (Kwach and colleagues, BMC Infectious Diseases, 2025). The trial therefore cannot tell us whether doxy-PEP would work for women who take it reliably, or in places where resistance differs.

Official guidance reflects that gap. CDC recommends that providers discuss doxy-PEP with gay, bisexual and other men who have sex with men and transgender women who have had a bacterial STI in the last 12 months, says there is insufficient evidence to weigh benefits and harms in other groups, and calls studies in cisgender women vital (CDC, Doxy PEP for Bacterial STI Prevention, 2024). In May 2026 the World Health Organization issued its first doxy-PEP recommendation, for the same two groups (WHO, 2026). CDC also lists open questions about antibiotic resistance and the body's helpful bacteria with long-term use.

What that means for women in the lifestyle, and for heterosexual men, who were not studied either: the proven tools are condoms or dental dams used every time, regular testing that includes the throat and rectum where relevant, and vaccines and HIV prevention your clinician recommends. CDC's own doxy-PEP page points people towards regular testing, HIV prevention options including PrEP, and hepatitis A and B vaccination. If you are interested in doxy-PEP, raise it with a sexual-health clinician, who can explain the current evidence for your situation and decide whether to prescribe. CDC notes that a doxy-PEP dose is not enough to treat an STI you already have, and that prescriptions should not be shared.

This is general information, not medical advice. JoinTheSwing does not provide testing, prescriptions or health verification. The JoinTheSwing doxy-PEP and play-safe guides cover how doxy-PEP compares with PrEP, condoms and vaccines.